Skip to main content

Table 4 Change from baseline to EoT in MoCA subscale scores (SAF)

From: Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)

Change, mean (SD)Placebo (n = 411)Mirabegron Total (n = 425)
Attention Points−0.0 (0.9)−0.1 (0.9)
Language Points0.0 (0.7)0.0 (0.7)
Naming Points−0.0 (0.4)0.0 (0.4)
Visuospatial/Executive Points0.0 (1.0)−0.1 (1.2)
Abstraction Points0.0 (0.5)−0.0 (0.5)
Delayed Recall Points0.2 (1.4)0.2 (1.3)
Orientation Points−0.0 (0.4)−0.0 (0.4)
  1. EoT end of treatment, MoCA Montreal Cognitive Assessment, SAF safety analysis set, SD standard deviation
\